Pictured: Sign on top of Johnson & Johnson’s office in Madrid, Spain/iStock, BrasilNut1
Johnson & Johnson reported first-quarter 2024 earnings on Tuesday, posting a 2.3% increase in sales buoyed by the strong performance of its oncology and immunology businesses….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
